Ignite Creation Date:
2025-12-24 @ 5:47 PM
Ignite Modification Date:
2025-12-28 @ 12:52 AM
Study NCT ID:
NCT06926868
Status:
RECRUITING
Last Update Posted:
2025-12-15
First Post:
2025-04-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-09-11
Start Date Type:
ACTUAL
Primary Completion Date:
2028-03-13
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-05-15
Completion Date Type:
ESTIMATED
First Submit Date:
2025-04-08
First Submit QC Date:
None
Study First Post Date:
2025-04-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-09
Last Update Post Date:
2025-12-15
Last Update Post Date Type:
ESTIMATED